GLP-1/GCG Dual Agonist LIGHT-COG (NCT07083154)

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

Overview

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

Overview

The LIGHT-COG Study (NCT07083154) is a Phase 3 clinical trial investigating the efficacy, safety, and tolerability of a GLP-1/GCG (Glucagon) Dual Receptor Agonist in patients with Type 2 Diabetes and early dementia, particularly Alzheimer's disease["@diabetes2021"].

This trial represents a novel therapeutic approach targeting the metabolic dysfunction hypothesis of neurodegeneration, leveraging the neuroprotective effects of GLP-1 receptor agonism. It is one of the first large-scale Phase 3 trials to directly test whether metabolic modulation can slow cognitive decline in AD patients with diabetes.

Trial Information

| Field | Value |
|-------|-------|
| NCT Number | [NCT07083154](https://clinicaltrials.gov/study/NCT07083154) |
| Status | Recruiting |
| Phase | Phase 3 |
| Enrollment | 420 participants (estimated) |
| Study Type | Interventional |
| Allocation | Randomized, parallel-group |
| Intervention Model | Double-blind, placebo-controlled |
| Start Date | September 27, 2025 |
| Completion Date | August 1, 2029 |
| Primary Outcome | Integrated Alzheimer's Disease Rating Scale (iADRS) Score Change[@iadrsscale] |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |

Study Design

Arms

| Arm | Intervention | Dose | Duration |
|-----|--------------|------|----------|
| Active | GLP-1/GCG Dual Agonist | TBD | 52 weeks |
| Placebo | Matching placebo | N/A | 52 weeks |

Primary Endpoint

• Change in iADRS (Integrated Alzheimer's Disease Rating Scale) score from baseline to Week 52
• The iADRS combines cognitive testing (ADAS-Cog) with functional assessment (ADCS-ADL)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Scientific Rationale

Type 2 Diabetes and Alzheimer's Disease Link

Epidemiological studies have established a strong link between Type 2 Diabetes and increased risk of Alzheimer's disease. The metabolic dysfunction in diabetes contributes to[@type3diabetes]:

• Brain insulin resistance reduces glucose utilization
• Neuronal energy crisis contributes to dysfunction
• Impaired insulin signaling affects synaptic plasticity

• Chronic low-grade inflammation in diabetes
• Activated microglia produce pro-inflammatory cytokines
• Neuroinflammation accelerates tau pathology

• Mitochondrial dysfunction from chronic hyperglycemia
• Advanced glycation end-products (AGEs) accumulate
• Antioxidant systems become overwhelmed

• Diabetes impairs endothelial function
• Reduced clearance of Aβ from brain
• Increased leakiness allows peripheral toxins into CNS

The "Type 3 Diabetes" Hypothesis

Emerging evidence supports the concept of Alzheimer's disease as a form of diabetes[@type3diabetes]:

• Brain insulin resistance: AD brains show reduced insulin receptor expression and signaling
• Impaired glucose uptake: FDG-PET shows hypometabolism in AD-affected regions
• Aβ effects on insulin signaling: Aβ oligomers interfere with insulin receptor function
• Tau effects on glucose metabolism: Tau pathology disrupts insulin signaling

GLP-1 Receptor Agonists as Neuroprotective Agents

GLP-1 receptor agonists, originally developed for diabetes treatment, have shown neuroprotective properties in preclinical models[@glp1neuroprotection]:

| Mechanism | Effect |
|-----------|--------|
| Insulin sensitization | Enhances brain insulin sensitivity |
| Anti-inflammatory | Reduces microglial activation |
| Anti-apoptotic | Prevents neuronal death |
| Synaptic protection | Preserves synaptic function |
| Aβ reduction | Decreases amyloid plaque formation |
| Tau modulation | Reduces tau phosphorylation |
| Autophagy enhancement | Improves protein clearance |
| Mitochondrial function | Preserves neuronal energy metabolism |

Why Dual GLP-1/GCG Agonism?

The dual GLP-1/GCG agonist may provide enhanced neuroprotection:

GLP-1 Receptor Effects

• Enhances insulin sensitivity in the brain
• Reduces neuroinflammation
• Promotes synaptic plasticity and neurogenesis
• Decreases amyloid-beta toxicity

GCG Receptor Effects

• Regulates glucose metabolism
• Modulates hepatic glucose output
• May improve cerebral energy metabolism
• Enhances lipolysis and energy expenditure

Clinical Sites

Participating Institutions (China)

| Institution | City | Province |
|-------------|------|----------|
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University | Nanjing | Jiangsu |
| Nanjing First Hospital, Nanjing Medical University | Nanjing | Jiangsu |
| Shanghai General Hospital, Shanghai Jiao Tong University | Shanghai | Shanghai |
| Xiangya Hospital of Central South University | Changsha | Hunan |
| Huadong Hospital | Nanjing | Jiangsu |
| Jiangsu Province Hospital of Traditional Chinese Medicine | Nanjing | Jiangsu |
| Changzhou No.2 People's Hospital | Changzhou | Jiangsu |
| The Second Affiliated Hospital of Dalian Medical University | Dalian | Liaoning |

Biomarker Program

Target Engagement

Disease Progression Markers

Imaging

• MRI: Hippocampal atrophy rate
• FDG-PET: Cerebral glucose metabolism
• Amyloid PET: (subset) Amyloid plaque burden

Competitive Landscape

GLP-1 Agonists in Alzheimer's Disease

| Drug | Company | Phase | Status | Mechanism |
|------|---------|-------|--------|-----------|
| LIGHT-COG | Nanjing Drum Tower | Phase 3 | Recruiting | GLP-1/GCG dual |
| Semaglutide | Novo Nordisk | Phase 3 | Completed | GLP-1 |
| Liraglutide | Novo Nordisk | Phase 2 | Completed | GLP-1 |
| Exenatide | AstraZeneca | Phase 2 | Completed | GLP-1 |
| Dapagliflozin | BMS | Phase 2 | Recruiting | SGLT2 |

Metabolic Therapies in Development

| Approach | Target | Development Stage |
|----------|--------|------------------|
| GLP-1/GIP dual | GLP-1/GIP receptors | Phase 2-3 |
| GLP-1/GCG dual | GLP-1/GCC receptors | Phase 3 |
| SGLT2 inhibitors | Glucose reabsorption | Phase 2 |
| Insulin sensitizers | PPARγ | Phase 2 |
| Metabolic modulators | mTOR, AMPK | Preclinical |

Why This Trial Matters

1. Addressing the Comorbidity

• ~30% of AD patients have Type 2 Diabetes
• Diabetes accelerates cognitive decline
• No approved therapies addressing this comorbidity

2. Disease-Modifying Potential

• Targets underlying metabolic dysfunction rather than just symptoms
• Addresses both peripheral and central pathology
• May slow progression rather than merely symptomatic benefit

3. Large Phase 3 Trial

• 420 participants provides robust efficacy data
• 52-week duration adequate for detecting clinical benefit
• Comprehensive biomarker program to understand mechanism

4. Unmet Medical Need

• No approved therapies for Alzheimer's that target metabolic pathways
• Current AD treatments (cholinesterase inhibitors, memantine) provide limited benefit
• Metabolic approaches offer a novel mechanism of action

5. Potential for Precision Medicine

• May identify responders based on metabolic status
• Biomarker program will inform personalized treatment approaches
• Could lead to combination therapies for diabetes-AD patients

Safety Considerations

Expected Adverse Events

| Event | Frequency | Management |
|-------|-----------|------------|
| Nausea | Common (20-30%) | Gradual titration, anti-emetics |
| Vomiting | Less common (5-10%) | Dose adjustment |
| Diarrhea | Common (10-15%) | Supportive care |
| Hypoglycemia | Rare (2-3%) | Monitor, adjust diabetes meds |
| Pancreatitis | Rare (<1%) | Immediate discontinuation |

Monitoring Plan

• Regular blood glucose monitoring
• Adverse event assessment at each visit
• Pancreatic enzyme monitoring (amylase, lipase)
• Cardiovascular monitoring (ECG, vital signs)

Regulatory Considerations

China NMPA Context

• This trial is conducted under China NMPA regulations
• Results may support approval in China
• International multi-regional trials may follow

Potential for Global Development

• Success could lead to global Phase 3 program
• GLP-1 agonists have established safety profiles
• May pursue FDA/EMA approval for AD indication

Current Status (March 2026)

The LIGHT-COG trial is actively recruiting as of March 2026. Enrollment is expected to complete by mid-2027, with topline results in 2029.

Milestones:

• September 2025: First patient enrolled
• December 2025: 50 patients enrolled
• Target: 420 patients by mid-2027

Clinical Significance

This trial is significant because:

If Positive

• Would support "Type 3 diabetes" hypothesis
• Could lead to GLP-1 agonist approval for AD
• Would validate metabolic approach more broadly
• May expand to non-diabetic AD patients

If Negative

• Would not necessarily refute metabolic hypothesis
• Could indicate wrong target or inadequate dosing
• May inform combination therapy approaches
• Would guide future trial designs

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease overview
• [Type 3 Diabetes Hypothesis](/mechanisms/type-3-diabetes-ad) — Mechanism
• [GLP-1 and Neuroprotection](/therapeutics/glp-1-agonists-neurodegeneration) — Drug class
• [Metabolic Syndrome and Alzheimer's Disease](/mechanisms/metabolic-dysfunction-neurodegeneration) — Mechanism
• [Diabetes and Dementia Risk](/diseases/diabetes-dementia-link) — Comorbidity

References